Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Ocugen stock

Own Ocugen stock in just a few minutes.

Posted

Fact checked

Ocugen, Inc is a biotechnology business based in the US. Ocugen shares (OCGN) are listed on the NASDAQ and all prices are listed in US Dollars. Ocugen employs 16 staff and has a trailing 12-month revenue of around USD$42,620.

How to buy shares in Ocugen

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Ocugen Find the stock by name or ticker symbol: OCGN. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Ocugen reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Ocugen, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Ocugen. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Ocugen share price

Use our graph to track the performance of OCGN stocks over time.

Ocugen shares at a glance

Information last updated 2020-09-25.
52-week rangeUSD$0.17 - USD$8.62
50-day moving average USD$0.4173
200-day moving average USD$0.3399
Wall St. target priceUSD$0.7
PE ratio 0.0467
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-4.8349

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Available asset types Stock trade fee Option trade fee Annual fee
Vanguard
Stocks,Mutual funds,ETFs,Forex
$0
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
Stocks,Options,ETFs,Cryptocurrency
$0
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
TD Ameritrade
Stocks,Bonds,Options,Mutual funds,ETFs,Forex,Futures
$0
or $25 If it is broker-assisted
$0 + $0.65/contract,
or $25 Broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Interactive Brokers
Stocks,Bonds,Options,Mutual funds,Index funds,ETFs,Forex,Futures,Cash
$0
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
Stocks,Options,ETFs,Futures
$0
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Ocugen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Ocugen price performance over time

Historical closes compared with the last close of $N/A

1 week (2020-09-17) -100.00%
1 month (2020-08-27) -100.00%
3 months (2020-06-26) -100.00%
6 months (2020-03-26) -100.00%
1 year (2019-09-26) -100.00%
2 years (2018-09-26) -100.00%
3 years (2017-09-26) -100.00%
5 years (2015-09-25) -100.00%

Is Ocugen under- or over-valued?

Valuing Ocugen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ocugen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Ocugen's P/E ratio

Ocugen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Ocugen shares trade at around 0x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Ocugen financials

Revenue TTM USD$42,620
Gross profit TTM USD$0
Return on assets TTM -60.93%
Return on equity TTM -421.47%
Profit margin 0%
Book value N/A
Market capitalisation USD$40.1 million

TTM: trailing 12 months

Shorting Ocugen shares

There are currently 5.0 million Ocugen shares held short by investors – that's known as Ocugen's "short interest". This figure is 18.2% down from 6.1 million last month.

There are a few different ways that this level of interest in shorting Ocugen shares can be evaluated.

Ocugen's "short interest ratio" (SIR)

Ocugen's "short interest ratio" (SIR) is the quantity of Ocugen shares currently shorted divided by the average quantity of Ocugen shares traded daily (recently around 21.5 million). Ocugen's SIR currently stands at 0.23. In other words for every 100,000 Ocugen shares traded daily on the market, roughly 230 shares are currently held short.

However Ocugen's short interest can also be evaluated against the total number of Ocugen shares, or, against the total number of tradable Ocugen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ocugen's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Ocugen shares in existence, roughly 40 shares are currently held short) or 0.0381% of the tradable shares (for every 100,000 tradable Ocugen shares, roughly 38 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Ocugen.

Find out more about how you can short Ocugen stock.

Ocugen share dividends

We're not expecting Ocugen to pay a dividend over the next 12 months.

Have Ocugen's shares ever split?

Ocugen's shares were split on a 1:60 basis on 30 September 2019. So if you had owned 60 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ocugen shares – just the quantity. However, indirectly, the new 5900% higher share price could have impacted the market appetite for Ocugen shares which in turn could have impacted Ocugen's share price.

Ocugen overview

Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site